title: [Effects by androgen suppression with luteinizing hormone on cognitive functions in men treated for cancer of prostate].
abstract: OBJECTIVE
  To evaluate secondary effects on cognitive functions as memory and attention impairments in men treated by androgen suppression for cancer of prostate.
  
  
  METHODS
  A prospective study on men treated with luteinizing hormone-realising hormone analogues (LH-RH analogues) for cancer of prostate was designed. Eighteen men were evaluated with cognitive tests as Mini Mental State (MMS), memory evaluation (Grober-Buschke, Rey Test), attention and executive test (Trail Making Test and Montgomery Asberg Depression Rating Scale [MADRS]) before beginning androgen suppression. Base line pretreatment assessments of every patient were compared with similar tests after six and 12 months of hormone therapy.
  
  
  RESULTS
  On 18 patients, 14 were eligible with pretreatment-median PSA of 22ng/ml (13-659), testosterone of 477ng/dl (398-583), which decreased to 1 and 37ng/dl, respectively. Visual-memory test (Rey test) was significantly improved at M6 (p: 0,001) and M12 (p: 0,02) as was the inversed number-memory test (WAIS) after M6 of androgen suppression and (p: 0,03).
  
  
  CONCLUSIONS
  After 12 months of androgen suppression, global cognitive performances were preserved. Our results failed to observe impairment of cognitive function. This deserves more important prospective study.
authors.affiliation: Service de neurologie, centre hospitalier de la Rochelle, Poitiers, France.
authors.forename: C
authors.initials: C
authors.lastname: Nedelec
authors.forename: S
authors.initials: S
authors.lastname: Ragot
authors.forename: J
authors.initials: J
authors.lastname: Irani
authors.forename: C
authors.initials: C
authors.lastname: Pires
authors.forename: R
authors.initials: R
authors.lastname: Gil
authors.forename: B
authors.initials: B
authors.lastname: Doré
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000494:pharmacology* / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects*; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone